Endocyte, Inc.

$ECYT - Nasdaq - Pharmaceuticals and Biotechnology
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 1
WATCHLISTS

COMMUNIQUÉ DETAILS

posts/post

Press Release $ECYT Endocyte, Inc.

0 COMMENTs 18 Jul
Up 0 0 Down
Endocyte Announces Second Quarter 2013 Earnings Conference Call

WEST LAFAYETTE, Ind., July 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Thursday, Aug. 1, at 4:30 p.m. EDT to discuss its second quarter 2013 financial results and provide an operational update.

Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investor Relations section of the Company's website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).

A replay of the call will be available beginning at 7:30 p.m. EDT on Aug. 1, until midnight EDT on Aug. 7, 2013. To access the replay, please dial (855) 859-2056 (U.S./Canada) or (404) 537-3406 (International) and reference the conference 16506274. Additionally, the webcast will be recorded and available on the Company's website for two weeks following the call.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,
         (212) 362-1200, stephanie@sternir.com
         Martina Schwarzkopf, Ph.D., Russo Partners,
         (212) 845-4292, martina.schwarzkopf@russopartnersllc.com
         Tony Russo, Ph.D., Russo Partners,
         (212) 845-4251, tony.russo@russopartnersllc.com
Source: Endocyte, Inc.
SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/9HK

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?